Philips Gradually Re-Enters CPAP Markets
Customers are welcoming Philips Respironics CPAP devices back in markets around the globe, according to Philips CEO Roy Jakobs.
Customers are welcoming Philips Respironics CPAP devices back in markets around the globe, according to Philips CEO Roy Jakobs.
The FDA has requested Philips conduct additional testing on its recalled CPAP, BiPAP, and ventilator devices, calling testing to date inadequate to fully evaluate the risks posed to users.
The national consortium of law firms will advance the carriage of a class action related to the recall of Philips’ CPAP and ventilator devices.
Philips Respironics provided the latest results and conclusions on the comprehensive test and research program to assess potential health risks related to the polyester-based polyurethane sound abatement foam in specific sleep therapy and ventilator devices under the voluntary June 2021 recall.
Read MorePhilips Respironics provided an update on the field action for specific sleep therapy and ventilator devices involved in the company’s ongoing recall.
Read MoreThe FDA updated its Philips Respironics recall safety communication to provide updated information about medical device reports that the agency received from Jan 1 to March 31.
Read MoreRoyal Philips’ CEO says the third-party risk assessments for the sleep therapy devices under the June 2021 recall are “positive and reassuring.”
Read MorePhilips provides an update on field action for specific sleep therapy and ventilator devices involved in the company’s ongoing recall.
Read MoreECRI released its annual Top 10 Health Technology Hazards report, and its biggest safety concern directly relates to sleep medicine.
Read MoreRoyal Philips announced a new chief business leader for its connected care businesses, bringing on a seasoned healthcare leader with experience in the sleep space.
Read MoreThe FDA updated its safety communication on the Philips’ recall to include reporting of medical device reports received from August 1 to October 31, 2022.
Read MoreWhen Philips Respironics issued a CPAP recall affecting millions of patients, sleep physicians and patients alike scrambled to identify alternative treatments for sleep apnea. Many of them found a solution in oral appliance therapy.
Read MoreNew data suggests suggest CPAP pressure relief might be best placed where we least expect it.
Read MorePhilips has initiated productivity actions, including simplifying the organization to streamline the way of working and reduce expenses.
Read MoreThe new classification comes after the FDA announced a Philips Respironics recall of certain BiPAP and CPAP masks due to a serious safety concern related to magnetic headgear clips that may cause harm to people who have implanted medical devices.
Read MorePhilips’ performance in the third quarter was impacted by continued supply chain challenges that were more significant than anticipated.
Read MoreThe FDA announced the recall of certain Philips Respironics CPAP and BiPAP masks due to a safety concern involving magnets.
Read MoreThe settlement resolves a lawsuit originally brought by a Respironics’ employee under the whistleblower provisions of the False Claims Act.
Read More